Deschloroetizolam Stats & Data

Deschloroetizolam is a thienotriazolodiazepine closely related to etizolam; drug checking programs describe it as roughly half as strong per milligram and lasting up to about twice as long as etizolam, which increases next-day impairment risk; plan activities accordingly. Community and HR sources consistently flag benzodiazepines combined with alcohol, opioids, or GHB/GBL as dangerous due to additive/synergistic respiratory depression; avoid these combinations entirely and place any unresponsive person in the recovery position while seeking emergency help. Tramadol with benzodiazepines is particularly risky because it adds respiratory/CNS depression and has seizure potential; avoid this pairing. Etizolam (the parent compound) is primarily metabolized by CYP3A4; given close structural similarity, deschloroetizolam may be similarly affected—CYP3A4 inhibitors (azole antifungals, macrolides, grapefruit) can raise levels and prolong effects; dose conservatively and avoid redosing if such inhibitors are on board. Potency is in the low-milligram range; use a calibrated 0.001 g scale or volumetric dosing and ensure complete dissolution—do not rely on cloudy suspensions as uneven distribution can cause accidental overdoses and blackouts. Illicit supply variability is high; drug checking services have repeatedly detected deschloroetizolam—sometimes unexpectedly—in fentanyl samples; if any opioid exposure is possible, keep naloxone available (it reverses opioids, not benzodiazepines) and avoid using alone. Regular use builds tolerance quickly and can produce significant dependence; abrupt cessation after sustained use can trigger severe withdrawal and seizures—seek medical supervision for any taper. Flumazenil can reverse benzodiazepine effects in medical settings but may precipitate seizures in benzodiazepine-dependent people or mixed overdoses; it must not be self-administered. Avoid driving or operating machinery for at least a full waking day after significant doses due to amnesia, impaired coordination, and residual sedation. Because formal human pharmacokinetic data are limited, all timelines should be treated as approximate; start low, wait full onset and peak, and avoid stacking doses.